In Ewing sarcoma, small molecule YK-4-279 and its clinical derivative TK-216 have been labelled as first-in-class inhibitors of EWSR1::FLI1 and other EWSR1 fusions seen in Ewing sarcoma. This evidence concerns the gene EWSR1 and Ewing sarcoma.